Search Results

You are looking at 21 - 30 of 487 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Jashodeep Datta, Matthew T. McMillan, Eric K. Shang, Ronac Mamtani, Russell S. Lewis Jr, Rachel R. Kelz, Ursina Teitelbaum, John P. Plastaras, Jeffrey A. Drebin, Douglas L. Fraker, Giorgos C. Karakousis, and Robert E. Roses

guidelines, visit NCCN.org ). 11 The latter recommendation reflects findings from the CLASSIC trial; specifically, improved DFS and OS in patients receiving adjuvant chemotherapy (capecitabine/oxaliplatin) compared with those undergoing surgery alone. 11

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

): Abstract 3500 . 80 Kuebler JP Wieand S O’Connell MJ . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 . J Clin Oncol 2007 ; 25

Full access

Lee S. Schwartzberg and Sarah L. Blair

without pertuzumab. Of note, a careful assessment of cardiac risk should be performed in this patient population. Figure 2. Recommendations for adjuvant chemotherapy in older patients with breast cancer. Abbreviation: OS, overall survival

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

. Am J Surg 2006 ; 192 : 873 – 877 . 111 Wolmark N Wieand HS Hyams DM . Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project

Full access

Maxwell T. Vergo and Al B. Benson III

compared with those with stage II (T4b–a,N0), with 5-year survivals of 83% to 91% versus 58% to 79%, respectively, 5 and yet are offered adjuvant chemotherapy. Evidence shows that stage II and III disease have very similar gene expression profiles and

Full access

Jeffrey Allen and Mohammad Jahanzeb

Edited by Kerrin G. Robinson

trials. Non-small Cell Lung Cancer Collaborative Group . BMJ 1995 ; 311 : 899 – 909 . 6. Arriagada R Bergman B Dunant A . Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer . N Engl J Med

Full access

Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, and Christopher Willett

All patients who have resected polyps should undergo total colonoscopy to rule out other synchronous polyps, and should subsequently undergo appropriate follow-up surveillance endoscopy. 64 Adjuvant chemotherapy is not recommended for patients with

Full access

Samuel W. Beenken and Marshall M. Urist

Merkel cell carcinoma (MCC) or neuroendocrine carcinoma of the skin is uncommon, often aggressive, and has a poor prognosis. Complete surgical excision with histologic documentation of clear resection margins is recommended for the primary cancer. Retrospective analysis of clinical data strongly suggests that adjuvant radiotherapy improves local control of MCC, but no evidence has been published that it prolongs survival. Sentinel lymph node biopsy is a useful method of determining the need for regional lymph node dissection in stage I patients. Chemotherapy regimens similar to those employed for small cell carcinoma of the lung have been recommended for advanced MCC. Patients often show an initial response to therapy, but it is usually short-lived. The three-year overall survival for patients with MCC is 31%. Before an improvement in long-term survival can be realized, early detection, appropriate use of surgery and radiation therapy, and the development of effective systemic chemotherapy are required.